Natural Killer Cell Immunotherapy After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia Patients: Phase I Clinical Trial.

Stem Cell Rev RepAug 3, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)Open access

Shiva Eskandarian, Amirhossein Izadpanah, Saye Parkhideh et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase I clinical trial evaluated the safety and efficacy of interleukin-15-activated CD56+ cell infusion in patients with acute leukemia post-allogeneic hematopoietic stem cell transplantation. While survival rates did not differ statistically between groups, a trend towards improved survival was noted in the intervention group, particularly in patients with complete remission who had higher NK cell percentages on day +40.

Key findings

  • CD56+ cell infusion was safe with no complications reported.
  • A trend towards improved survival was observed in the intervention group.
  • Patients in complete remission had a higher percentage of NK cells on day +40 compared to those with graft rejection or relapse.

Why it matters

The study highlights the potential of NK cell immunotherapy in enhancing immune responses post-transplantation, which may lead to better patient outcomes in acute leukemia management.

Source

PubMed · PMID 42545587Free full text on PubMed Central

Published in Stem Cell Rev Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.